glp-1 treatment phoenix Weight Loss for Arizona | Affinity Whole Health GLP-1s | AgelessRx

Resistance training, adequate protein intake, sleep, and nutrition are not optional additions to GLP-1 therapy

Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future

Diabetes Metabolic Syndrome: Clin Res Reviews

How GLP-1 Receptor Agonists Can Help With Diabetes With that important disclosure out of the way, here are the most common diabetes-related benefits associated with Ozempic and potentially other GLP-1 receptor agonists

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status